NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis $1.82 +0.09 (+5.20%) (As of 10/4/2024) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Reneo Pharmaceuticals Stock (NASDAQ:RPHM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Reneo Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.68▼$1.9050-Day Range$1.31▼$1.8252-Week Range$0.98▼$9.21Volume437,500 shsAverage Volume250,384 shsMarket Capitalization$60.84 millionP/E RatioN/ADividend YieldN/APrice Target$11.01Consensus RatingReduce Company OverviewReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Reneo Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks36th Percentile Overall ScoreRPHM MarketRank™: Reneo Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 810th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingReneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageReneo Pharmaceuticals has received no research coverage in the past 90 days.Read more about Reneo Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.65) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Reneo Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.65% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.65% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for RPHM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $355,105.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reneo Pharmaceuticals' insider trading history. Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RPHM Stock News HeadlinesCormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals SharesOctober 11, 2024 | finance.yahoo.comDeep Track Capital's Strategic Investment in Reneo PharmaceuticalsOctober 11, 2024 | finance.yahoo.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 29, 2024 | Porter & Company (Ad)Carlyle Group Inc. Reduces Stake in Reneo Pharmaceuticals Inc.October 10, 2024 | finance.yahoo.comReneo Pharmaceuticals: Navigating Financial Challenges and Corporate ChangesOctober 9, 2024 | finance.yahoo.comOnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 MillionOctober 4, 2024 | globenewswire.comBaosheng Media Gr (NASDAQ:BAOS) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comReneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKureOctober 2, 2024 | globenewswire.comSee More Headlines RPHM Stock Analysis - Frequently Asked Questions How have RPHM shares performed this year? Reneo Pharmaceuticals' stock was trading at $1.60 at the start of the year. Since then, RPHM shares have increased by 13.8% and is now trading at $1.82. View the best growth stocks for 2024 here. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. When did Reneo Pharmaceuticals IPO? Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Reneo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Reneo Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Invesco QQQ (QQQ), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings8/13/2024Today10/28/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$11.01 High Stock Price Target$35.55 Low Stock Price Target$1.50 Potential Upside/Downside+505.1%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.52% Return on Assets-56.36% Debt Debt-to-Equity RatioN/A Current Ratio57.86 Quick Ratio57.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book0.68Miscellaneous Outstanding Shares33,430,000Free Float27,439,000Market Cap$60.84 million OptionableOptionable Beta0.21 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:RPHM) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reneo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.